Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written permission from parent or legal guardian~2. Age younger than 91 days~3. Likely to survive beyond the first 48 hours after enrollment~4. Sufficient intravascular access (either peripheral or central) to receive study drug.~   AND ONE OF THE FOLLOWING~5. 1) Physical, radiological, and/or bacteriological findings of a complicated intra-abdominal infection. These include peritonitis, NEC (Necrotizing Enterocolitis) Grade II or higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous perforation, meconium ileus with perforation, bowel obstruction with perforation, as evidenced by free peritoneal air on abdominal radiograph, intestinal pneumatosis or portal venous gas on abdominal radiographic examination.~OR 2) Possible NEC OR 3) Otherwise receiving meropenem per local standard of care~Exclusion criteria:~1. Renal dysfunction evidenced by urine output \<0.5 mL/hr/kg over the prior 24 hours~2. Serum creatinine \>1.7 mg/dL~3. History of clinical seizures or EEG (Electroencephalogram) confirmed seizures~4. Concomitant treatment with another carbapenem (ertapenem or imipenem) at the time of informed consent~5. Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Meropenem (Type: EXPERIMENTAL): These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA \<2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and \<91 days; Group 3: GA at birth 32 weeks or older - PNA \<2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and \<91 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).